Local Anesthesia for TAVR Was Safe and Reduced Hospital Stays

A minimalist approach to transcatheter aortic valve replacement (TAVR) involving local anesthesia appears to have several advantages, according to this new meta-analysis.

 

In addition to shortening times for procedures and lengths of stay in the critical care unit and hospital, lighter sedation may lower the need for transfusions or treatment with inotropes or vasopressors.

 

Those benefits do not come with clinical complications. In fact, mortality at 30 days was lower in those receiving TAVR with local anesthesia (3.7% vs. 4.2%; risk ratio [RR]: 0.76; 95% confidence interval [CI]: 0.64-0.92).

 

In the earlier days of TAVR, procedures were typically performed under general anesthesia with orotracheal intubation. However, in time, accumulating evidence suggested that using local anesthesia in the procedure, as part of a minimalist approach, is not only feasible but also beneficial.

 

While the meta-analysis is not to be considered as definitive evidence as regards hard endpoints such as mortality, a minimalist strategy presents enough advantages to support its application.

 

This meta-analysis included 27 studies and a total of 24,085 patients.

 

Most procedural variables turned out to be similar for both strategies, including rates of stroke, acute myocardial infarction, renal failure, vascular complications, major bleeding, a need for a permanent pacemaker, paravalvular insufficiency, or fluoroscopy time.

 

Patients who received local anesthesia presented the following advantages:

  • a shorter average procedure time (90 vs. 127 minutes),
  • less time in the critical care unit (1.5 vs. 3.0 days),
  • less time in the hospital (5 vs 9 days),
  • possibly, lower mortality (although this conclusion might be biased).

 

Original title: Comparison of Local Versus General Anesthesia in Patients Undergoing Transcatheter Aortic Valve Replacement: A Meta-Analysis and Meta-Regression.

Presenter: Villablanca PA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...